<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529359</url>
  </required_header>
  <id_info>
    <org_study_id>PiLeJe-LactiTol-0210</org_study_id>
    <nct_id>NCT01529359</nct_id>
  </id_info>
  <brief_title>Irritable Bowel Syndrome and Lactibiane Tolerance</brief_title>
  <official_title>Effect of Lactibiane Tolerance on Symptoms Severity of Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PiLeJe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Larena SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of a probiotic combination (Lactibiane&#xD;
      Tolerance) on the severity of symptoms in patients with irritable bowel syndrome (IBS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to evaluate the effects of a probiotic combination&#xD;
      (Lactibiane Tolerance) on the severity of symptoms in patients with irritable bowel syndrome&#xD;
      (IBS).&#xD;
&#xD;
      The secondary purposes are to evaluate the effects of the intervention on:&#xD;
&#xD;
        -  quality of life&#xD;
&#xD;
        -  severity of fatigue, anxiety and depression&#xD;
&#xD;
        -  levels of inflammatory markers in blood and tools&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2010</start_date>
  <completion_date type="Actual">February 11, 2013</completion_date>
  <primary_completion_date type="Actual">February 4, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of bowel symptoms according to the Francis Score</measure>
    <time_frame>After 6 weeks of complementation</time_frame>
    <description>The severity of bowel symptoms is evaluated with a quality of life questionnaire, the Francis Score before and after 6 weeks of complementation in placebo and verum groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>after 6 weeks of complementation</time_frame>
    <description>Effect of the intervention on transit and abdominal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Anxiety/Depression</measure>
    <time_frame>after 6 weeks of complementation</time_frame>
    <description>The level of anxiety/depression will be measured with the HAD scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the complementation on fatigue</measure>
    <time_frame>after 6 weeks of complementation</time_frame>
    <description>The level of fatigue will be measured with the score to the fatigue Impact Scale (FIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the intervention on immunological parameters in stools</measure>
    <time_frame>after 6 weeks of complementation</time_frame>
    <description>The effects of the intervention on immunological parameters in stools will be evaluated via the levels of beta-defensine 2 and sérine protease activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the intervention on immunological parameters in blood</measure>
    <time_frame>after 6 weeks of complementation</time_frame>
    <description>The impact of the intervention on immunological parameters in blood will be measured with levels of endotoxines, ultrasensitive protein C Reactive and cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of bowel symptoms according to the Francis Score</measure>
    <time_frame>after 2 weeks of wash-out</time_frame>
    <description>The severity of bowel symptoms is evaluated with the Francis Score before 6 weeks of complementation and after 2 weeks of wash-out in placebo and verum groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>after 2 weeks of wash-out</time_frame>
    <description>Effect of the intervention on transit and abdominal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severity of the anxiety/depression</measure>
    <time_frame>after 2 weeks of wash-out</time_frame>
    <description>The level of anxiety/depression will be measured with the HAD scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the complementation on fatigue</measure>
    <time_frame>After 2 weeks of wash out</time_frame>
    <description>The level of fatigue will be measured with the score to the fatigue Impact Scale (FIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the intervention on immunological parameters in stools</measure>
    <time_frame>after 2 weeks of wash out</time_frame>
    <description>The effects of the intervention on immunological parameters in stools will be avaluated via the levels of beta-defensine 2 and sérine protease activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the intervention on immunological parameters in blood</measure>
    <time_frame>after 2 weeks of wash-out</time_frame>
    <description>The impact of the intervention on immunological parameters in blood will be measured with levels of endotoxines, ultrasensitive protein C Reactive and cytokines</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Probiotics Excipients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactibiane Tolerance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotics combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactibiane Tolerance</intervention_name>
    <description>Probiotics combination 2 gelules per days during 6 weeks</description>
    <arm_group_label>Lactibiane Tolerance</arm_group_label>
    <other_name>Probiotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 2 gelules per days for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Irritable bowel syndrome according to the Rome II criteria&#xD;
&#xD;
          -  150&lt; Francis Score &lt; 300&#xD;
&#xD;
          -  HAD score inferior or egal to 25&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to one of the composant of the product&#xD;
&#xD;
          -  Use of probiotics or antibiotics last four weeks&#xD;
&#xD;
          -  use of prohibited drugs&#xD;
&#xD;
          -  bowel preparation for morphological examination last month&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  immundepressed or co-existing other serious illness or evolutive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piche Thierry, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Chu L'Archet 2</name>
      <address>
        <city>Nice</city>
        <state>Alpes Maritimes</state>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2012</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

